186 related articles for article (PubMed ID: 36047093)
41. [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
Yang Y; Xia ZJ; Zhang WH; Fu CC; Bao L; Chen B; Ding KY; Wang SL; Luo J; Li BZ; Hua LM; Yang W; Zhou X; Wang L; Xu TH; Wang WD; Wu GL; Huang Y; Li J; Liu P
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):628-634. PubMed ID: 34547867
[No Abstract] [Full Text] [Related]
42. Endocrine Evaluation in POEMS Syndrome: A Cohort Study.
Yang H; Zhao H; Gao X; Huang X; Cao X; Zhou D; Xia W; Li J
Front Endocrinol (Lausanne); 2020; 11():536241. PubMed ID: 33193075
[TBL] [Abstract][Full Text] [Related]
43. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome.
Kanai K; Kuwabara S; Misawa S; Hattori T
Intern Med; 2007; 46(6):311-3. PubMed ID: 17380000
[TBL] [Abstract][Full Text] [Related]
44. POEMS Syndrome: Therapeutic Options.
Jaccard A
Hematol Oncol Clin North Am; 2018 Feb; 32(1):141-151. PubMed ID: 29157615
[TBL] [Abstract][Full Text] [Related]
45. POEMS syndrome: origination from clonal plasma cells or B cells?
Zhou L; Lu J; Lin Z; Wang X; Luo L; Wang C; Hong L; Xu R; Huang H
Hematology; 2023 Dec; 28(1):2186044. PubMed ID: 36897012
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Royer B; Merlusca L; Abraham J; Musset L; Haroche J; Choquet S; Leleu X; Sebban C; Decaux O; Galicier L; Roussel M; Recher C; Banos A; Guichard I; Brisseau JM; Godmer P; Hermine O; Deplanque G; Facon T; Asli B; Leblond V; Fermand JP; Marolleau JP; Jaccard A
Am J Hematol; 2013 Mar; 88(3):207-12. PubMed ID: 23335406
[TBL] [Abstract][Full Text] [Related]
47. [Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
Takakuwa T; Araki T; Miura A; Fujitani Y; Takeoka Y; Ohta K; Yamamura R
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1043-1047. PubMed ID: 31273172
[TBL] [Abstract][Full Text] [Related]
48. Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma.
Hatano K; Orimo K; Ogura M; Okabe S; Ishida T; Kubota A; Shimizu J; Hashida H
Intern Med; 2023 Feb; 62(3):475-479. PubMed ID: 35831107
[TBL] [Abstract][Full Text] [Related]
49. Raynaud's phenomenon and positive antinuclear antibodies as first manifestation of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes): a case report.
Torres-Saavedra F; León-Sierra L
BMC Rheumatol; 2022 May; 6(1):26. PubMed ID: 35585632
[TBL] [Abstract][Full Text] [Related]
50. Two cases of special POEMS syndrome without monoclonal protein expression: a case report and literature review.
Du HP; Zhang Y; Sun LM; Luo L
J Int Med Res; 2021 Apr; 49(4):300060521990967. PubMed ID: 33820466
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome.
Cai QQ; Wang C; Cao XX; Cai H; Zhou DB; Li J
Eur J Haematol; 2015 Oct; 95(4):325-30. PubMed ID: 25401269
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients.
Fang F; Lan XX; Hu RH; Hui WH; Zhao H; Guo YX; Ji BX; Liu HJ; Su L; Sun WL
Ther Adv Neurol Disord; 2024; 17():17562864231219151. PubMed ID: 38288324
[TBL] [Abstract][Full Text] [Related]
53. Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone.
Yang H; Huang X; Cai Q; Wang C; Cao X; Zhou D; Li J
Orphanet J Rare Dis; 2016 Jun; 11(1):80. PubMed ID: 27317315
[TBL] [Abstract][Full Text] [Related]
54. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome.
Kuwabara S; Misawa S; Kanai K; Sawai S; Hattori T; Nishimura M; Nakaseko C
J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1255-7. PubMed ID: 18469028
[TBL] [Abstract][Full Text] [Related]
55. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome.
Li J; Zhang W; Jiao L; Duan MH; Guan HZ; Zhu WG; Tian Z; Zhou DB
Blood; 2011 Jun; 117(24):6445-9. PubMed ID: 21393478
[TBL] [Abstract][Full Text] [Related]
56. [POEMS syndrome: monoclonal plasma cell disorder with polyneuropathy].
Kamezaki K; Nagafuji K
Nihon Rinsho; 2007 Dec; 65(12):2235-7. PubMed ID: 18069266
[TBL] [Abstract][Full Text] [Related]
57. Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome.
Yokouchi H; Baba T; Misawa S; Oshitari T; Kuwabara S; Yamamoto S
Br J Ophthalmol; 2020 Jan; 104(1):33-38. PubMed ID: 30914422
[TBL] [Abstract][Full Text] [Related]
58. Regular assessment of serum vascular endothelial growth factor levels to monitor POEMS syndrome.
Gentile F; Terenghi F; Doneddu PE; De Lorenzo A; Giannotta C; Giordano A; Mazza R; Nozza A; Nobile-Orazio E
Neurol Sci; 2024 Feb; 45(2):727-733. PubMed ID: 37702830
[TBL] [Abstract][Full Text] [Related]
59. Ocular findings in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome.
Kaushik M; Pulido JS; Abreu R; Amselem L; Dispenzieri A
Ophthalmology; 2011 Apr; 118(4):778-82. PubMed ID: 21035860
[TBL] [Abstract][Full Text] [Related]
60. Unraveling the Neurological Complexity of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, and Skin Changes Syndrome: A Report of a Challenging Case of a Young Woman and Cutting-Edge Advancements in the Field.
Furciniti G; Casalino G; Lo Russo FM; Bolli N; Meneri M; Comi GP; Corti SP; Velardo D
Diseases; 2023 Nov; 11(4):. PubMed ID: 37987277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
